The Development of selective and potent Kv1.3 ion channel blockers for the treatment of multiple sclerosis

Funding Activity

Website
http://purl.org/au-research/grants/nhmrc/406698

Funding Status
Closed

Does something not look right? The information on this page has been harvested from data sources that may not be up to date. We continue to work with information providers to improve coverage and quality. To report an issue, use the .

Funded Activity Summary

Building on the well-established path of developing drugs from Nature, the amplification of some unusual qualities of a naturally-occurring substance, khellinone, could lead to new treatments for autoimmune diseases such as multiple sclerosis and diabetes. Designed variants of khellinone are known to be very effective at preventing the destructive impact of the body's own T cells on the central nervous system that occurs in autoimmune disease.

Funded Activity Details

Start Date: 01-01-2006

End Date: 01-01-2009

Funding Scheme: Early Career Fellowships

Funding Amount: $233,187.00

Funder: National Health and Medical Research Council

Research Topics

ANZSRC Field of Research (FoR)

Autoimmunity

ANZSRC Socio-Economic Objective (SEO)

There are no SEO codes available for this funding activity

Other Keywords

Drug Development | Ion Channel blocker | Kv1.3 | Medicinal chemistry | Multiple Sclerosis

Related Links